Delivering the right treatment to the right patient at the right time
Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2013 we received a total of 13 approvals in the United States, Europe and Japan.
Learn more about Novartis pharmaceuticals in your country:
Key pharmaceutical products marketed by Novartis are listed below in alphabetical order:
Voltaren/Cataflam (diclofenac sodium/potassium/resinate/free acid)
Coartem/Riamet (artemether and lumefantrine)
Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide)